Elevated endogenous secretory receptor for advanced glycation end products (esRAGE) levels are associated with circulating soluble RAGE levels in diabetic children
-
Reiko Saito
,
Yukiyo Yamamoto
Abstract
Background:
Advanced glycation end products (AGEs) and the receptor for AGE (RAGE) play an important role in the development of diabetic vascular complications. This study aimed at investigating the relationship between the soluble form of RAGE (sRAGE), endogenous secretory RAGE (esRAGE), and pentosidine in childhood diabetes.
Methods:
The study included 18 children with type 1 diabetes mellitus (T1DM), 10 with type 2 DM (T2DM), and 22 age-matched, non-diabetic children (control).
Results:
Serum sRAGE levels in the T1DM (2557.7 pg/mL) were significantly higher than both T2DM (1956.4 pg/mL) and control (1658.5 pg/mL). The circulating levels of esRAGE in T1DM and T2DM children were similar, but significantly higher than those of control. Serum pentosidine levels in the T1DM group were positively correlated with serum sRAGE and esRAGE levels, but not with anthropometric or biochemical measurements. The duration of diabetes and esRAGE levels were independent predictors of the circulating sRAGE levels.
Conclusions:
Unlike adults, children with diabetes exhibit high circulating esRAGE levels, and both sRAGE and esRAGE levels are correlated with pentosidine levels. These results suggest that circulating sRAGE and esRAGE in children may be surrogate markers for progressive glucose toxicity in pediatric patients with childhood-onset diabetes.
Acknowledgments
The authors thank Miss Yuki Ohga for her technical assistance.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This work was supported by the Health Science Research Grant for Research on Applying Health Technology [Jitsuyoka (Nanbyo)-Ippan-014] from the Ministry of Health, Labour and Welfare (MHLW), Japan (to Shunsuke Araki) and by a Grant-in-Aid for Scientific Research #21591340 (to Yukiyo Yamamoto) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025–3110.1038/2012Suche in Google Scholar
2. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:129–46.10.1007/s001250051591Suche in Google Scholar
3. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002;105:816–22.10.1161/hc0702.104183Suche in Google Scholar
4. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597–605.10.1161/CIRCULATIONAHA.106.621854Suche in Google Scholar
5. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998–5004.10.1016/S0021-9258(18)42138-2Suche in Google Scholar
6. Vazzana N, Santilli F, Cuccurullo C, Davi G. Soluble forms of RAGE in internal medicine. Intern Emerg Med 2009;4:389–401.10.1007/s11739-009-0300-1Suche in Google Scholar PubMed
7. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097–109.10.1042/bj20021371Suche in Google Scholar PubMed PubMed Central
8. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008;57:2461–9.10.2337/db07-1808Suche in Google Scholar PubMed PubMed Central
9. Toth C, Rong LL, Yang C, Martinez J, Song F, et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008;57:1002–17.10.2337/db07-0339Suche in Google Scholar PubMed
10. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261–8.10.1172/JCI11771Suche in Google Scholar PubMed PubMed Central
11. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Res 2008;5:190–7.10.3132/dvdr.2008.031Suche in Google Scholar PubMed
12. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25:2587–93.10.1161/01.ATV.0000190660.32863.cdSuche in Google Scholar PubMed
13. Accacha S, Rosenfeld W, Jacobson A, Michel L, Schnurr FJ, et al. Plasma advanced glycation end products (AGEs), receptors for AGEs and their correlation with inflammatory markers in middle school-age children. Horm Res Paediatr 2013;80:318–27.10.1159/000354831Suche in Google Scholar PubMed
14. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 2007;23:368–71.10.1002/dmrr.690Suche in Google Scholar PubMed
15. Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem 2005;51:1749–50.10.1373/clinchem.2005.051961Suche in Google Scholar PubMed
16. Sakurai S, Yamamoto Y, Tamei H, Matsuki H, Obata K, et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 2006;73:158–65.10.1016/j.diabres.2005.12.013Suche in Google Scholar PubMed
17. Devangelio E, Santilli F, Formoso G, Ferroni P, Bucciarelli L, et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007;43:511–8.10.1016/j.freeradbiomed.2007.03.015Suche in Google Scholar PubMed
18. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, et al. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006;49:2756–62.10.1007/s00125-006-0394-1Suche in Google Scholar PubMed
19. Galler A, Muller G, Schinzel R, Kratzsch J, Kiess W, et al. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA. Diabetes Care 2003;26:2609–15.10.2337/diacare.26.9.2609Suche in Google Scholar PubMed
20. Koutroumani N, Partsalaki I, Lamari F, Dettoraki A, Gil AP, et al. Protective mechanisms against oxidative stress and angiopathy in young patients with diabetes type 1 (DM1). J Pediatr Endocrinol Metab 2013;26:309–17.10.1515/jpem-2012-0183Suche in Google Scholar PubMed
21. Miyata T, Taneda S, Kawai R, Ueda Y, Horiuchi S, et al. Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci U.S.A 1996;93:2353–8.10.1073/pnas.93.6.2353Suche in Google Scholar
22. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem 1989;264:21597–602.10.1016/S0021-9258(20)88225-8Suche in Google Scholar
23. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 2010;21:195–214.10.1007/s00198-009-1066-zSuche in Google Scholar PubMed
24. Kerkeni M, Saidi A, Bouzidi H, Letaief A, Ben Yahia S, et al. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab Vasc Dis Res 2013;10:239–45.10.1177/1479164112460253Suche in Google Scholar PubMed
25. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008;93:1013–9.10.1210/jc.2007-1270Suche in Google Scholar PubMed
26. Dettoraki A, Gil AP, Spiliotis BE. Association between serum levels of the soluble receptor (sRAGE) for advanced glycation endproducts (AGEs) and their receptor (RAGE) in peripheral blood mononuclear cells of children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009;22:895–904.10.1515/JPEM.2009.22.10.895Suche in Google Scholar PubMed
27. Yamamoto Y, Yamamoto H. Receptor for advanced glycation end-products-mediated inflammation and diabetic vascular complications. J Diabetes Investig 2011;2:155–7.10.1111/j.2040-1124.2011.00125.xSuche in Google Scholar PubMed PubMed Central
28. Choi KM, Han KA, Ahn HJ, Hwang SY, Hong HC, et al. Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial. J Clin Endocrinol Metab 2012;97:3751–8.10.1210/jc.2012-1951Suche in Google Scholar PubMed
29. Di Pino A, Urbano F, Zagami RM, Filippello A, Di Mauro S, et al. Low endogenous secretory receptor for advanced glycation end-products levels are associated with inflammation and carotid atherosclerosis in prediabetes. J Clin Endocrinol Metab 2016;101:1701–9.10.1210/jc.2015-4069Suche in Google Scholar PubMed
30. Sebekova K, Somoza V, Jarcuskova M, Heidland A, Podracka L. Plasma advanced glycation end products are decreased in obese children compared with lean controls. Int J Pediatr Obes 2009;4:112–8.10.1080/17477160802248039Suche in Google Scholar PubMed
31. Chiavaroli V, D’Adamo E, Giannini C, de Giorgis T, De Marco S, et al. Serum levels of receptors for advanced glycation end products in normal-weight and obese children born small and large for gestational age. Diabetes Care 2012;35:1361–3.10.2337/dc11-2302Suche in Google Scholar PubMed PubMed Central
32. Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004;95:233–8.10.1161/01.RES.0000137876.28454.64Suche in Google Scholar PubMed
33. Yamagishi S, Yonekura H, Yamamoto Y, Katsuno K, Sato F, et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997;272:8723–30.10.1074/jbc.272.13.8723Suche in Google Scholar PubMed
34. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005;54:1–7.10.2337/diabetes.54.1.1Suche in Google Scholar PubMed
35. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007;13:185–9.10.2119/2006-00090.NakamuraSuche in Google Scholar
36. Yamagishi S, Adachi H, Takeuchi M, Enomoto M, Furuki K, et al. Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res 2007;39:845–8.10.1055/s-2007-991176Suche in Google Scholar PubMed
37. Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 2007;8:1138–43.10.2174/138945007782151298Suche in Google Scholar PubMed
38. Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006;55:1227–31.10.1016/j.metabol.2006.05.007Suche in Google Scholar PubMed
39. Ng ZX, Chua KH, Iqbal T, Kuppusamy UR. Soluble receptor for advanced glycation end-product (sRAGE)/pentosidine ratio: a potential risk factor determinant for type 2 diabetic retinopathy. Int J Mol Sci 2013;14:7480–91.10.3390/ijms14047480Suche in Google Scholar PubMed PubMed Central
40. Salonen KM, Ryhanen SJ, Forbes JM, Borg DJ, Harkonen T, et al. Decrease in circulating concentrations of soluble receptors for advanced glycation end products at the time of seroconversion to autoantibody positivity in children with prediabetes. Diabetes Care 2015;38:665–70.10.2337/dc14-1186Suche in Google Scholar PubMed
41. Miura J, Uchigata Y, Yamamoto Y, Takeuchi M, Sakurai S, et al. AGE down-regulation of monocyte RAGE expression and its association with diabetic complications in type 1 diabetes. J Diabetes Complications 2004;18:53–9.10.1016/S1056-8727(02)00281-7Suche in Google Scholar
©2017 Walter de Gruyter GmbH, Berlin/Boston
Artikel in diesem Heft
- Frontmatter
- Editorial
- Disorders of sex development
- Original Articles
- Fertility and sexual function: a gap in training in pediatric endocrinology
- Disorders of sex development in children in KwaZulu-Natal Durban South Africa: 20-year experience in a tertiary centre
- Novel mutations of the SRD5A2 and AR genes in Thai patients with 46, XY disorders of sex development
- Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard?
- Anti-hyperglycemic activity of Aegle marmelos (L.) corr. is partly mediated by increased insulin secretion, α-amylase inhibition, and retardation of glucose absorption
- Risk factors that affect metabolic health status in obese children
- Nocturnal levels of chemerin and progranulin in adolescents: influence of sex, body mass index, glucose metabolism and sleep
- Elevated endogenous secretory receptor for advanced glycation end products (esRAGE) levels are associated with circulating soluble RAGE levels in diabetic children
- Food exchange estimation by children with type 1 diabetes at summer camp
- Usefulness of non-fasting lipid parameters in children
- Monitoring steroid replacement therapy in children with congenital adrenal hyperplasia
- Clinical and molecular characterization of Beckwith-Wiedemann syndrome in a Chinese population
- An analysis of the sequence of the BAD gene among patients with maturity-onset diabetes of the young (MODY)
- Case Reports
- Hypogonadotropic hypogonadism in a female patient with congenital arhinia
- Transdermal testosterone gel for induction and continuation of puberty in adolescent boys with hepatic dysfunction
- Long-term response to growth hormone therapy in a patient with short stature caused by a novel heterozygous mutation in NPR2
- Three cases of Japanese acromicric/geleophysic dysplasia with FBN1 mutations: a comparison of clinical and radiological features
Artikel in diesem Heft
- Frontmatter
- Editorial
- Disorders of sex development
- Original Articles
- Fertility and sexual function: a gap in training in pediatric endocrinology
- Disorders of sex development in children in KwaZulu-Natal Durban South Africa: 20-year experience in a tertiary centre
- Novel mutations of the SRD5A2 and AR genes in Thai patients with 46, XY disorders of sex development
- Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard?
- Anti-hyperglycemic activity of Aegle marmelos (L.) corr. is partly mediated by increased insulin secretion, α-amylase inhibition, and retardation of glucose absorption
- Risk factors that affect metabolic health status in obese children
- Nocturnal levels of chemerin and progranulin in adolescents: influence of sex, body mass index, glucose metabolism and sleep
- Elevated endogenous secretory receptor for advanced glycation end products (esRAGE) levels are associated with circulating soluble RAGE levels in diabetic children
- Food exchange estimation by children with type 1 diabetes at summer camp
- Usefulness of non-fasting lipid parameters in children
- Monitoring steroid replacement therapy in children with congenital adrenal hyperplasia
- Clinical and molecular characterization of Beckwith-Wiedemann syndrome in a Chinese population
- An analysis of the sequence of the BAD gene among patients with maturity-onset diabetes of the young (MODY)
- Case Reports
- Hypogonadotropic hypogonadism in a female patient with congenital arhinia
- Transdermal testosterone gel for induction and continuation of puberty in adolescent boys with hepatic dysfunction
- Long-term response to growth hormone therapy in a patient with short stature caused by a novel heterozygous mutation in NPR2
- Three cases of Japanese acromicric/geleophysic dysplasia with FBN1 mutations: a comparison of clinical and radiological features
